1246 related articles for article (PubMed ID: 28785997)
1. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
4. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
6. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
8. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
9. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Immunotherapy: Picking a Winner.
Teng MW; Khanna R; Smyth MJ
Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
[TBL] [Abstract][Full Text] [Related]
13. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Rivera Vargas T; Apetoh L
Front Immunol; 2019; 10():1181. PubMed ID: 31191545
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
15. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
18. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
Economopoulou P; Kotsantis I; Psyrri A
Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
